Members
Meet the scientists.
| Welcome to the M&M Lab.
Led by Mala Shanmugam, we study the role of Metabolism in Myeloma.
Research
Learn about what we're working on.
Publications
Read our recent papers.
Members
|
Mala Shanmugam, PhD, MS, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University, School of Medicine. Dr. Shanmugam is a member of the Cancer Cell Biology Research Program and the Molecular and Systems Pharmacology at GDBBS Emory. Dr. Shanmugam attended Madurai Kamaraj University in T. Nadu, India where she earned a MS in Biotechnology. She received her PhD in Tumor Cell Biology from Northwestern University Medical School in Chicago, IL. She completed her fellowship training at Northwestern University Medical School and at Loyola University of Chicago Medical Center. |
Associate Scientist |
Education: Institute of Microbial Technology, Jawaharlal Nehru University (PhD, Molecular Biology) CSJM University (MS, Biotechnology) Lucknow University (BS, Botany/Chemistry) Research Focus: Multiple Myeloma, Apoptosis, BCL-2 proteins, Metabolism Email: richa.bajpai@emory.edu |
Postdoctoral Scholar |
Education: Georgia Tech (MS+PhD, Bioengineering) IIT Delhi (BS+MT, Biochemical Engineering and Biotechnology) Research Focus: Lung Adenocarcinoma, Collective Cell Invasion, Metabolism Email: aditi.sharma@emory.edu |
Research Specialist |
Education: Georgia Tech (BS, Biomedical Engineering) Research Focus: Multiple Myeloma, Apoptosis, BCL-2 proteins, Metabolism Email: arusha.ayesha.siddiqa@emory.edu |
Summer Intern |
Education: Emory (Rising junior, Chemistry and Biology) Email: kim.amelsberg@emory.edu |
Emory Scholar Intern |
Education: Choate High School (Rising senior) Email: ewedge19@choate.edu |
Research
The central interest of our lab is to understand how metabolism regulates cellular function with the objective of identifying metabolic vulnerabilities that can be targeted to regulate specific biology. In this context we investigate therapy resistance and the BCL-2 family of proteins in multiple myeloma and the metabolic basis of invasion/metastasis in lung adenocarcinoma.We use metabolite profiling, metabolite flux and cellular bioenergetics assays and examine signaling in the context of biochemical, cellular and molecular interventions to investigate these questions in cell line, patient sample and in vivo models. Our long-term goals are thus:
- To better understand the functional implications of altered cellular metabolism in cancer
- To elucidate how nutrient metabolism signals to promote cancer cell survival and metastasis
- To investigate cancer metabolism as a conduit to understanding therapy resistance that can be perturbed to orchestrate potent strategies of synthetic lethality with existing therapy
Publications
Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer.
Wei C, Heitmeier M, Hruz PW, Shanmugam M.
Methods in Molecular Biology, 2018
Development of GLUT4-selective antagonists for multiple myeloma therapy
Changyong Wei, Richa Bajpai, Horrick Sharma, Monique Heitmeier, Atul D. Jain, Shannon M. Matulis, Ajay K. Nooka,
Rama K. Mishra, Paul W. Hruz, Gary E. Schiltz, Mala Shanmugam
European Journal of Medicinal Chemistry, 2017
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to ABT-199
Richa Bajpai, Shannon M Matulis, Changyong Wei, Ajay K Nooka, Hayley E Von Holen, Sagar Lonial, Lawrence H Boise
and Mala Shanmugam
Oncogene, 2016
In Silico Modeling-based Identification of GLUT4 Selective Inhibitors for Cancer Therapy
Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM, Nooka AK, Rosen ST, Hruz PW, Schiltz GE, Shanmugam M.
Journal of Biological Chemistry, 2015 See more